LAG-3 has quickly emerged from a niche immunological target to a central point of interest across cancer treatment, immuno-oncology combinations, and autoimmune disease research. As exploration of immune checkpoints extends beyond PD-1/PD-…

The MET signaling axis has established itself as a prominent focus of scientific research and commercial activity within oncology. As precision-based medicine advances, MET inhibitors are receiving increased attention for their capacity to…